04:39 , Aug 1, 2019 |  BC Innovations  |  Distillery Therapeutics

DEGS1 inhibition for insulin resistance and hepatic steatosis

DISEASE CATEGORY: Endocrine/metabolic; hepatic INDICATION: Diabetes; hepatic A University of Utah team led by Centaurus Therapeutics Inc. co-founder Scott Summers showed that DEGS1 inhibition could treat and prevent insulin resistance and hepatic steatosis. In mice...
08:00 , Feb 4, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: δ-4-desaturase sphingolipid 1 (DEGS1)

Cancer INDICATION: Prostate cancer Cell culture studies identified a DEGS1 inhibitor that could help treat prostate cancer. Chemical synthesis and in vitro testing of oxadiazole analogs identified a compound that decreased conversion of the DEGS1...